Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma (VIRASKIN)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Merkel Cell Carcinoma of Skin

Study type: Observational

Funder types: Other

Identifiers

NCT06780475

APHP240470

2024-A00643-44 (Registry Identifier)

Details and patient eligibility

About

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Full description

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Enrollment: 15 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients >= 18 years old;
• Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
• Informed for the study and no-opposed for participation;
• Affiliated with a social security scheme or in an equivalent situation.

Exclusion criteria

• Patients ongoing another interventional clinical trial;
• Patients under guardianship or trusteeship;
• Pregnancy or breastfeed;
• Patients refusal.